Desmopressin is a lab-made version of vasopressin, the hormone that tells the kidneys to hold on to water. This guide covers its structure, mechanism, approvals, key studies and label warnings. Sources checked November 17, 2026.
Quick answer: Desmopressin is a prescription peptide drug that copies the water-saving action of vasopressin. It acts mainly on V2 receptors in the kidney, and it also raises the clotting protein factor VIII. FDA approved it for central diabetes insipidus, bedwetting, and some mild bleeding disorders.
Vitrapep does not sell desmopressin; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is desmopressin?
Desmopressin is “a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin,” according to the DDAVP label revised in February 2021 (DDAVP label, 2021). It differs from vasopressin in two places. The ChEBI entry in PubChem says 3-mercaptopropionic acid replaces the cysteine at position 1. Position 8 holds D-arginine, the mirror-image form of the amino acid (PubChem CID 5311065).
Desmopressin belongs to the vasopressin analog class. PubChem lists its formula as C46H64N14O12S2 and its molecular weight as 1069.2 g/mol. The labels describe the acetate salt trihydrate, which has a molecular weight of 1183.34. For background on hormone peptides, see our overview of peptide hormones.
FDA first approved desmopressin on February 21, 1978, as DDAVP. Drugs@FDA lists it under NDA 017922, now discontinued (Drugs@FDA). Other DDAVP products remain on the market. DESMODA was approved on February 25, 2026, while Noctiva and Nocdurna are discontinued (Drugs@FDA data).
Desmopressin: key facts
| Fact | Detail |
|---|---|
| Structure | Modified vasopressin: 3-mercaptopropionic acid at position 1, D-arginine at position 8 |
| Class | Vasopressin analog; acts mainly on V2 receptors |
| Molecular formula | C46H64N14O12S2 (PubChem) |
| Molecular weight | 1069.2 g/mol (PubChem) |
| First FDA approval | February 21, 1978 (DDAVP, NDA 017922) |
| Approved brands | DDAVP, DESMODA; discontinued: Noctiva, Nocdurna, Stimate, Minirin, Concentraid |
How does desmopressin work?
The DDAVP label revised in July 2022 describes two actions (DDAVP label, 2022). First, desmopressin stimulates vasopressin 2 (V2) receptors in the kidney. That increases water reabsorption and so reduces urine production. Second, it raises plasma factor VIII activity in people with hemophilia A and von Willebrand’s disease Type I.
The same label says the structural changes lengthened its action and weakened its effects on blood pressure and organ smooth muscle. It reports a mean terminal half-life of 2.8 hours (see peptide half-life). The DESMODA label also names V2 receptor binding as its primary action (DESMODA label).
What is desmopressin approved for?
The labels list these indications:
- Central diabetes insipidus (DDAVP; DESMODA, 2026): “antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus.” DDAVP also covers temporary excess urination and thirst after head trauma or pituitary surgery. It is not indicated for nephrogenic diabetes insipidus.
- Primary nocturnal enuresis (DDAVP, application approved 1995): “indicated for the management of primary nocturnal enuresis,” per the 2021 DDAVP label.
- Hemophilia A (DDAVP, application approved 1984): for patients with factor VIII levels above 5% and no factor VIII antibodies. It aims to maintain hemostasis around surgery and reduce bleeding.
- Von Willebrand’s disease, Type I (DDAVP): for mild to moderate disease with factor VIII levels above 5%. It is not indicated for severe Type I disease.
Noctiva was approved in 2017 for nocturia due to nocturnal polyuria in adults who wake two or more times a night to pass urine (Noctiva label). It is now listed as discontinued.
What did the key trials of desmopressin show?
The 1977 bleeding-disorder study. Mannucci and colleagues reported in The Lancet that desmopressin raised factor VIII activity in people with mild or moderate hemophilia and von Willebrand’s disease (Mannucci et al., 1977). Activity rose two- to six-fold. Eight patients then had dental extraction or major surgery, reported as successful. In an earlier group of four, two still needed plasma concentrates. This was a small, uncontrolled human study.
The DB3 and DB4 nocturia trials. These two randomized, double-blind, placebo-controlled Phase 3 trials supported Noctiva (NCT01357356, NCT01900704). A pooled analysis covered 1,333 adults aged 50 or older over 12 weeks (Kaminetsky et al., 2018). Nighttime voids fell by 1.4 and 1.5 per night in the two desmopressin groups, versus 1.2 with placebo. Both differences were significant (p < 0.0001). A drop of 50% or more occurred in 37.9% and 48.7% of the desmopressin groups, versus 30.3% with placebo.
What side effects does the desmopressin label list?
The DDAVP label revised in July 2022 carries a boxed warning: “DDAVP can cause hyponatremia.” It adds that severe hyponatremia “can be life-threatening, leading to seizures, coma, respiratory arrest, or death.” People at higher risk, such as those with excessive fluid intake, are contraindicated.
Its common adverse reactions include abdominal cramps, flushing, fluid retention, headache and hypersensitivity reactions. Others are high or low blood pressure, hyponatremia, nausea, fast heart rate and blood clots. These come from voluntary reports after approval, so their frequency cannot always be estimated.
The 2021 DDAVP label has no boxed warning. In its bedwetting trials, headache was the only possibly related event in at least 3% of patients: 4% versus 3% with placebo. The DESMODA label has no boxed warning either. Its most common reactions are headache, dizziness, nausea, abdominal pain, high blood pressure and diarrhea. The pooled Noctiva trial paper reports hyponatremia in 1.1% and 0% of the two desmopressin groups and 0.2% with placebo (Kaminetsky et al., 2018).
What is the regulatory status of desmopressin, and is it used in research?
Desmopressin is a prescription drug in the United States; Drugs@FDA lists the marketed DDAVP and DESMODA products as prescription. An FDA review from 2017 says FDA issued an alert on December 7, 2007, about severe hyponatremia with desmopressin (FDA risk review, 2017). The trigger was reports of hyponatremic seizures, mostly in children given certain desmopressin products for primary nocturnal enuresis. FDA then removed that indication from those products.
In sport, the World Anti-Doping Agency names desmopressin in section S5, Diuretics and Masking Agents, of its 2026 Prohibited List. S5 substances are prohibited at all times and are Specified Substances. Our guide to peptides on the 2026 WADA list explains the sections.
In research, ChEBI lists desmopressin’s roles as a diagnostic agent, a renal agent and a vasopressin receptor agonist. It also notes its use in tests of kidney function. A French Phase 3 trial is testing whether it prevents too-fast sodium correction in severe hyponatremia (NCT06020495).
Frequently asked questions about desmopressin
Is desmopressin a peptide?
Yes. It is a synthetic analog of the peptide hormone vasopressin, with changes at positions 1 and 8. See what peptides are.
How is desmopressin different from vasopressin?
The DDAVP label says its changes gave it longer action and less effect on blood pressure. Our vasopressin guide covers the parent hormone.
Does desmopressin have a boxed warning?
The DDAVP label revised in July 2022 has a boxed warning for hyponatremia. The 2021 DDAVP label and the DESMODA label do not.
Is desmopressin banned in sport?
Yes. WADA’s 2026 list names it in section S5, Diuretics and Masking Agents, prohibited at all times.
What to know now
- Structure: a modified vasopressin, changed at positions 1 and 8; C46H64N14O12S2, 1069.2 g/mol.
- First approval: DDAVP, February 21, 1978; DESMODA joined on February 25, 2026.
- Approved uses: central diabetes insipidus, primary nocturnal enuresis, and bleeding in mild hemophilia A and von Willebrand’s disease Type I.
- Main safety issue: hyponatremia, the subject of a boxed warning on one DDAVP label and a 2007 FDA alert.
- Sport: named in WADA S5 and prohibited at all times.
What we’re watching
Label updates for DESMODA, approved on February 25, 2026. The French Phase 3 trial NCT06020495, with primary completion expected in December 2027. And WADA’s next Prohibited List, to see whether desmopressin stays in S5.